Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
28.55
-0.51 (-1.75%)
At close: Nov 5, 2026, 4:00 PM EST
29.56
+1.01 (3.54%)
After-hours: Nov 5, 2026, 7:30 PM EST

Viridian Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
26.3170.850.30.311.772.96
Revenue Growth
-62.83%23359.93%-3.82%-82.28%-40.20%182.19%
Gross Profit
-283.73-268.08-237.95-159.45-99.12-53.92
Operating Income
-468.66-363.4-299.04-254.45-134.3-79.73
Net Income
-397.6-281.93-208.56-175.01-87.04-79.41
Earnings Per Share
-3.80-3.32-3.07-3.91-2.71-6.66
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
955.21874.65717.58477.37424.55196.97
Total Debt
245.552.5921.122.045.260.52
Net Cash (Debt)
709.71822.06696.49455.33419.29196.45
Net Cash Growth
52.07%18.03%52.96%8.60%113.44%54.46%
Net Cash Per Share
6.799.6910.2610.1713.0716.48

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-341.51-276.39-232.32-184.17-93.84-54.58
Capital Expenditures
-1.94-0.5-0.51-0.9-0.8-0.34
Free Cash Flow
-343.44-276.89-232.83-185.07-94.64-54.92
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------
Operating Margin
-1781.38%-512.91%-99018.21%-81035.03%-7579.23%-2690.79%
Pretax Margin
-1724.06%-483.57%-89387.09%-75711.46%-7329.23%-2680.16%
Profit Margin
-1511.27%-397.93%-69059.60%-55734.71%-4912.13%-2680.15%
FCF Margin
-1305.42%-390.81%-77096.03%-58938.85%-5340.58%-1853.49%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
123.1041.925028.173647.53663.46144.94